-
The company Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) is happy to announce that a 2013 patent for its SepsetER TM sepsis diagnostic technology has been successfully registered. Australia and nations in Europe. It represents 400 million people in Sweden, Switzerland, and the United Kingdom. On August 29, 2022, the company received confirmation of European Patent (EP) 3117030 from its patent attorneys. Since that time, it has been granted to Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, and Spain. Additionally, on July 16, 2022, the corporation received an Australian Patent (Australian Patent No. AU2020201564B2).
Exclusively licensed to Sepset Biosciences Inc., a subsidiary of Asep Inc., these patents represent a proprietary, clinically viable AI for diagnosing sepsis, which kills more than 11 million people annually worldwide. It validates the base approach. The technology, called SepsetER, is a blood-based gene expression assay developed under the direction of Dr. Dr., senior microbiologist at UBC and founder and current CEO of Asep Inc. Robert E.W. Hancock. This test enables early and accurate diagnosis of severe cases of sepsis, a deadly disease. Sepsis is also the cause of death in most of his severe COVID-19 patients.
The patent also provides a solid foundation for our business as the test is in late-stage development and in preparation for formal 510(k) clinical trials. The SepsetER signature has already been validated and refined in over 700 sepsis and severe COVID-19 patients, so the company hopes to replicate this in formal studies. In diagnostics, the 510(k) pathway includes his single clinical trial, which, if successful, will lead to U.S. Food and Drug Administration (FDA) approval. If approved, the test will be marketed worldwide for use in emergency departments and intensive care units, enabling physicians to make earlier, informed decisions about patient care that improve prognosis and survival.
The SepsetER test detects the dysfunctional immune response underlying sepsis when a patient first enters the emergency room. This test is a blood-based gene expression assay that can be easily performed using equipment available in most hospital laboratories and provides results in approximately 60-90 minutes. Current diagnostic tools provide results in about 8 to 36 hours, often delaying initiation of treatment.
Managing Dr. Robert E.W. “Patents are the lifeblood of biotechnology,” Hancock said. “It demonstrates the novelty of our technology in key markets.”
SepsetER is intended to enable physicians to quickly predict disease severity and initiate emergency treatment for patients. Under this patent license agreement, Sepset Biosciences Inc., a subsidiary of Asep Inc., will receive exclusive worldwide rights to develop the Sepsis Severity Signature into a diagnostic test and commercialize that test.
COO Tim Murphy commented, “Expanding Asep Inc.’s patent coverage in Europe and Australia is an important step towards commercializing the SepsetER test for the company.”